Crescent Biopharma Prices $125M Public Offering of Shares & Warrants

Crescent Biopharma announced the pricing of its underwritten public offering, which includes 8,094,793 ordinary shares at $14.50 per share and pre-funded warrants for up to 525,897 ordinary shares at $14.499 per warrant. The offering is expected to generate approximately $125.0 million in gross proceeds for the company. Additionally, underwriters have been granted a 30-day option to purchase up to an extra 1,293,103 ordinary shares. The offering is anticipated to close on July 16, 2026.